HU227000B1 - Nmda receptor antagonist benzoyl urea derivatives, and pharmaceutical compositions containing them - Google Patents
Nmda receptor antagonist benzoyl urea derivatives, and pharmaceutical compositions containing them Download PDFInfo
- Publication number
- HU227000B1 HU227000B1 HU0401524A HUP0401524A HU227000B1 HU 227000 B1 HU227000 B1 HU 227000B1 HU 0401524 A HU0401524 A HU 0401524A HU P0401524 A HUP0401524 A HU P0401524A HU 227000 B1 HU227000 B1 HU 227000B1
- Authority
- HU
- Hungary
- Prior art keywords
- piperidine
- formula
- carboxylic acid
- hydroxy
- benzyl
- Prior art date
Links
- HRYILSDLIGTCOP-UHFFFAOYSA-N N-benzoylurea Chemical class NC(=O)NC(=O)C1=CC=CC=C1 HRYILSDLIGTCOP-UHFFFAOYSA-N 0.000 title claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 12
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title claims description 7
- 229940099433 NMDA receptor antagonist Drugs 0.000 title claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 95
- 238000000034 method Methods 0.000 claims description 72
- -1 hydroxy, benzyloxy, amino Chemical group 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 claims description 25
- 239000004480 active ingredient Substances 0.000 claims description 25
- 108010038912 Retinoid X Receptors Proteins 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 24
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000011347 resin Substances 0.000 claims description 13
- 229920005989 resin Polymers 0.000 claims description 13
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 12
- 208000002193 Pain Diseases 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
- 150000001412 amines Chemical class 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 230000036407 pain Effects 0.000 claims description 9
- QXSAKPUBHTZHKW-UHFFFAOYSA-N 4-hydroxybenzamide Chemical compound NC(=O)C1=CC=C(O)C=C1 QXSAKPUBHTZHKW-UHFFFAOYSA-N 0.000 claims description 8
- 239000002585 base Substances 0.000 claims description 8
- 239000012948 isocyanate Substances 0.000 claims description 8
- 150000002513 isocyanates Chemical class 0.000 claims description 8
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 7
- LURYMYITPCOQAU-UHFFFAOYSA-N benzoyl isocyanate Chemical compound O=C=NC(=O)C1=CC=CC=C1 LURYMYITPCOQAU-UHFFFAOYSA-N 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 claims description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 230000003287 optical effect Effects 0.000 claims description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 5
- 235000013355 food flavoring agent Nutrition 0.000 claims description 5
- HCGUJJPDXAJGAW-UHFFFAOYSA-N n-(4-hydroxybenzoyl)-4-[(3-methoxyphenyl)methyl]piperidine-1-carboxamide Chemical compound COC1=CC=CC(CC2CCN(CC2)C(=O)NC(=O)C=2C=CC(O)=CC=2)=C1 HCGUJJPDXAJGAW-UHFFFAOYSA-N 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- UVXVONNNSOZFTL-UHFFFAOYSA-N 4-benzylpiperidine-1-carboxylic acid Chemical compound C1CN(C(=O)O)CCC1CC1=CC=CC=C1 UVXVONNNSOZFTL-UHFFFAOYSA-N 0.000 claims description 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 208000004296 neuralgia Diseases 0.000 claims description 4
- 208000021722 neuropathic pain Diseases 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 150000003852 triazoles Chemical class 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- YHWMFDLNZGIJSD-UHFFFAOYSA-N 2h-1,4-oxazine Chemical compound C1OC=CN=C1 YHWMFDLNZGIJSD-UHFFFAOYSA-N 0.000 claims description 3
- ITXGAJCPAGYAJF-UHFFFAOYSA-N 4-[(4-chlorophenyl)methyl]-n-(4-hydroxybenzoyl)piperidine-1-carboxamide Chemical compound C1=CC(O)=CC=C1C(=O)NC(=O)N1CCC(CC=2C=CC(Cl)=CC=2)CC1 ITXGAJCPAGYAJF-UHFFFAOYSA-N 0.000 claims description 3
- SPUUORLTOKRGBY-UHFFFAOYSA-N 4-[(4-fluorophenyl)methyl]-n-(4-hydroxybenzoyl)piperidine-1-carboxamide Chemical compound C1=CC(O)=CC=C1C(=O)NC(=O)N1CCC(CC=2C=CC(F)=CC=2)CC1 SPUUORLTOKRGBY-UHFFFAOYSA-N 0.000 claims description 3
- SUQBNXQIAZGVKU-UHFFFAOYSA-N 4-benzyl-n-(4-hydroxybenzoyl)piperidine-1-carboxamide Chemical compound C1=CC(O)=CC=C1C(=O)NC(=O)N1CCC(CC=2C=CC=CC=2)CC1 SUQBNXQIAZGVKU-UHFFFAOYSA-N 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 claims description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 150000003936 benzamides Chemical class 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 229960003920 cocaine Drugs 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- MZISVEGLLHFXCG-UHFFFAOYSA-N n-(4-hydroxybenzoyl)-4-(phenylsulfanylmethyl)piperidine-1-carboxamide Chemical compound C1=CC(O)=CC=C1C(=O)NC(=O)N1CCC(CSC=2C=CC=CC=2)CC1 MZISVEGLLHFXCG-UHFFFAOYSA-N 0.000 claims description 3
- BTKGSXIFWKUVCZ-UHFFFAOYSA-N n-(4-hydroxybenzoyl)-4-[(4-methoxyphenyl)methyl]piperidine-1-carboxamide Chemical compound C1=CC(OC)=CC=C1CC1CCN(C(=O)NC(=O)C=2C=CC(O)=CC=2)CC1 BTKGSXIFWKUVCZ-UHFFFAOYSA-N 0.000 claims description 3
- WLMWGRLEGFSXPD-UHFFFAOYSA-N n-(4-hydroxybenzoyl)-4-[(4-methylphenyl)methyl]piperidine-1-carboxamide Chemical compound C1=CC(C)=CC=C1CC1CCN(C(=O)NC(=O)C=2C=CC(O)=CC=2)CC1 WLMWGRLEGFSXPD-UHFFFAOYSA-N 0.000 claims description 3
- 229940005483 opioid analgesics Drugs 0.000 claims description 3
- 230000003204 osmotic effect Effects 0.000 claims description 3
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 238000009736 wetting Methods 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 206010011878 Deafness Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000013016 Hypoglycemia Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000015114 central nervous system disease Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- 230000010370 hearing loss Effects 0.000 claims description 2
- 231100000888 hearing loss Toxicity 0.000 claims description 2
- 208000016354 hearing loss disease Diseases 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 125000005270 trialkylamine group Chemical group 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 3
- 239000007858 starting material Substances 0.000 claims 2
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims 1
- MENHXVNCWVKFRA-UHFFFAOYSA-N 1,4-oxazin-2-one Chemical group O=C1C=NC=CO1 MENHXVNCWVKFRA-UHFFFAOYSA-N 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 125000005236 alkanoylamino group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- NBGMRMDAEWWFIR-UHFFFAOYSA-N imidazole-2-thione Chemical compound S=C1N=CC=N1 NBGMRMDAEWWFIR-UHFFFAOYSA-N 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 28
- 239000011541 reaction mixture Substances 0.000 description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000005557 antagonist Substances 0.000 description 13
- 239000003480 eluent Substances 0.000 description 13
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 12
- 238000004440 column chromatography Methods 0.000 description 12
- 108091008634 hepatocyte nuclear factors 4 Proteins 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 11
- 239000003463 adsorbent Substances 0.000 description 10
- 239000011575 calcium Substances 0.000 description 10
- ICEKEZSKMGHZNT-UHFFFAOYSA-N 4-phenylmethoxybenzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1OCC1=CC=CC=C1 ICEKEZSKMGHZNT-UHFFFAOYSA-N 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 9
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 229910052791 calcium Inorganic materials 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 7
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- ABGXADJDTPFFSZ-UHFFFAOYSA-N 4-benzylpiperidine Chemical compound C=1C=CC=CC=1CC1CCNCC1 ABGXADJDTPFFSZ-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000829 suppository Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 102000034570 NR1 subfamily Human genes 0.000 description 5
- 108020001305 NR1 subfamily Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- LHOQRHIAIWDKIT-UHFFFAOYSA-N n-(4-aminobenzoyl)-4-benzylpiperidine-1-carboxamide Chemical compound C1=CC(N)=CC=C1C(=O)NC(=O)N1CCC(CC=2C=CC=CC=2)CC1 LHOQRHIAIWDKIT-UHFFFAOYSA-N 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960003998 ifenprodil Drugs 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- VOQMPZXAFLPTMM-UHFFFAOYSA-N 4-(4-chlorophenoxy)piperidine Chemical compound C1=CC(Cl)=CC=C1OC1CCNCC1 VOQMPZXAFLPTMM-UHFFFAOYSA-N 0.000 description 3
- DVCWUTSWCVQZSC-UHFFFAOYSA-N 4-(methanesulfonamido)benzamide Chemical compound CS(=O)(=O)NC1=CC=C(C(N)=O)C=C1 DVCWUTSWCVQZSC-UHFFFAOYSA-N 0.000 description 3
- XVVYSVVBPMJRAB-UHFFFAOYSA-N 4-acetamidobenzamide Chemical compound CC(=O)NC1=CC=C(C(N)=O)C=C1 XVVYSVVBPMJRAB-UHFFFAOYSA-N 0.000 description 3
- FCBQJNCAKZSIAH-UHFFFAOYSA-N 6-[2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]ethylsulfinyl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC(F)=CC=C1CC1CCN(CCS(=O)C=2C=C3OC(=O)NC3=CC=2)CC1 FCBQJNCAKZSIAH-UHFFFAOYSA-N 0.000 description 3
- FWYRCNFWCMKNTJ-UHFFFAOYSA-N 6-[3-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]propanoyl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC(F)=CC=C1CC1CCN(CCC(=O)C=2C=C3OC(=O)NC3=CC=2)CC1 FWYRCNFWCMKNTJ-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008119 colloidal silica Substances 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 108091008757 nuclear thyroid hormone receptors Proteins 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- ZVCDLGYNFYZZOK-UHFFFAOYSA-M sodium cyanate Chemical compound [Na]OC#N ZVCDLGYNFYZZOK-UHFFFAOYSA-M 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 description 2
- SHWZYKANRZAEAP-UHFFFAOYSA-N 1,3-benzothiazole-5-carboxamide Chemical compound NC(=O)C1=CC=C2SC=NC2=C1 SHWZYKANRZAEAP-UHFFFAOYSA-N 0.000 description 2
- OVUUVHGUUGUISC-UHFFFAOYSA-N 1-(4-fluorophenoxy)piperidine Chemical compound C1=CC(F)=CC=C1ON1CCCCC1 OVUUVHGUUGUISC-UHFFFAOYSA-N 0.000 description 2
- QEMSVZNTSXPFJA-HNAYVOBHSA-N 1-[(1s,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol Chemical compound C1([C@H](O)[C@H](C)N2CCC(O)(CC2)C=2C=CC=CC=2)=CC=C(O)C=C1 QEMSVZNTSXPFJA-HNAYVOBHSA-N 0.000 description 2
- DEASGFUXKKZMEV-UHFFFAOYSA-N 1-[(3-methoxyphenyl)methyl]piperidine Chemical compound COC1=CC=CC(CN2CCCCC2)=C1 DEASGFUXKKZMEV-UHFFFAOYSA-N 0.000 description 2
- VKMFDKYCIKEDMR-UHFFFAOYSA-N 1-[2-(4-hydroxyphenoxy)ethyl]-4-[(4-methylphenyl)methyl]-4-piperidinol Chemical compound C1=CC(C)=CC=C1CC1(O)CCN(CCOC=2C=CC(O)=CC=2)CC1 VKMFDKYCIKEDMR-UHFFFAOYSA-N 0.000 description 2
- IWGOGLJDYKPEFE-UHFFFAOYSA-N 2-oxo-3h-1,3-benzoxazole-6-carboxamide Chemical compound NC(=O)C1=CC=C2NC(=O)OC2=C1 IWGOGLJDYKPEFE-UHFFFAOYSA-N 0.000 description 2
- IIRKYWMNWGCABF-UHFFFAOYSA-N 3-(piperidin-4-ylmethyl)benzonitrile Chemical compound N#CC1=CC=CC(CC2CCNCC2)=C1 IIRKYWMNWGCABF-UHFFFAOYSA-N 0.000 description 2
- YRPZABIUCZZXLO-UHFFFAOYSA-N 4-(2-ethoxyphenoxy)-n-(4-hydroxybenzoyl)piperidine-1-carboxamide Chemical compound CCOC1=CC=CC=C1OC1CCN(C(=O)NC(=O)C=2C=CC(O)=CC=2)CC1 YRPZABIUCZZXLO-UHFFFAOYSA-N 0.000 description 2
- IPOFRRUDIUKVAL-UHFFFAOYSA-N 4-(2-ethoxyphenoxy)piperidine Chemical compound CCOC1=CC=CC=C1OC1CCNCC1 IPOFRRUDIUKVAL-UHFFFAOYSA-N 0.000 description 2
- PZDDFECYPRVIBQ-UHFFFAOYSA-N 4-(4-chlorophenoxy)-n-(4-hydroxybenzoyl)piperidine-1-carboxamide Chemical compound C1=CC(O)=CC=C1C(=O)NC(=O)N1CCC(OC=2C=CC(Cl)=CC=2)CC1 PZDDFECYPRVIBQ-UHFFFAOYSA-N 0.000 description 2
- YPBJUAAFANSSOZ-UHFFFAOYSA-N 4-(4-chlorophenoxy)-n-(4-phenylmethoxybenzoyl)piperidine-1-carboxamide Chemical compound C1=CC(Cl)=CC=C1OC1CCN(C(=O)NC(=O)C=2C=CC(OCC=3C=CC=CC=3)=CC=2)CC1 YPBJUAAFANSSOZ-UHFFFAOYSA-N 0.000 description 2
- JLAKCHGEEBPDQI-UHFFFAOYSA-N 4-(4-fluorobenzyl)piperidine Chemical compound C1=CC(F)=CC=C1CC1CCNCC1 JLAKCHGEEBPDQI-UHFFFAOYSA-N 0.000 description 2
- MJXSVXWQGBSOHJ-UHFFFAOYSA-N 4-(4-fluorophenoxy)-n-(4-hydroxybenzoyl)piperidine-1-carboxamide Chemical compound C1=CC(O)=CC=C1C(=O)NC(=O)N1CCC(OC=2C=CC(F)=CC=2)CC1 MJXSVXWQGBSOHJ-UHFFFAOYSA-N 0.000 description 2
- FEKDVXYNBLAULL-UHFFFAOYSA-N 4-(phenoxymethyl)-n-(4-phenylmethoxybenzoyl)piperidine-1-carboxamide Chemical compound C1CC(COC=2C=CC=CC=2)CCN1C(=O)NC(=O)C(C=C1)=CC=C1OCC1=CC=CC=C1 FEKDVXYNBLAULL-UHFFFAOYSA-N 0.000 description 2
- CMSVRAQQKBTLRF-UHFFFAOYSA-N 4-(phenylsulfanylmethyl)piperidine Chemical compound C1CNCCC1CSC1=CC=CC=C1 CMSVRAQQKBTLRF-UHFFFAOYSA-N 0.000 description 2
- MXDONVSSHRBYMN-UHFFFAOYSA-N 4-[(2,4-difluorophenyl)methyl]-n-(4-hydroxybenzoyl)piperidine-1-carboxamide Chemical compound C1=CC(O)=CC=C1C(=O)NC(=O)N1CCC(CC=2C(=CC(F)=CC=2)F)CC1 MXDONVSSHRBYMN-UHFFFAOYSA-N 0.000 description 2
- ONSQMJZUYDYVMR-UHFFFAOYSA-N 4-[(2,4-difluorophenyl)methyl]-n-(4-phenylmethoxybenzoyl)piperidine-1-carboxamide Chemical compound FC1=CC(F)=CC=C1CC1CCN(C(=O)NC(=O)C=2C=CC(OCC=3C=CC=CC=3)=CC=2)CC1 ONSQMJZUYDYVMR-UHFFFAOYSA-N 0.000 description 2
- VXQMAHFHVBQZHC-UHFFFAOYSA-N 4-[(2,4-difluorophenyl)methyl]piperidine Chemical compound FC1=CC(F)=CC=C1CC1CCNCC1 VXQMAHFHVBQZHC-UHFFFAOYSA-N 0.000 description 2
- JOBUJOXGDMPNPF-UHFFFAOYSA-N 4-[(3-cyanophenyl)methyl]-n-(4-hydroxybenzoyl)piperidine-1-carboxamide Chemical compound C1=CC(O)=CC=C1C(=O)NC(=O)N1CCC(CC=2C=C(C=CC=2)C#N)CC1 JOBUJOXGDMPNPF-UHFFFAOYSA-N 0.000 description 2
- HRWRTWHBWQERMW-UHFFFAOYSA-N 4-[(3-fluorophenyl)methyl]-n-(4-hydroxybenzoyl)piperidine-1-carboxamide Chemical compound C1=CC(O)=CC=C1C(=O)NC(=O)N1CCC(CC=2C=C(F)C=CC=2)CC1 HRWRTWHBWQERMW-UHFFFAOYSA-N 0.000 description 2
- ZXAPMANOWGBURM-UHFFFAOYSA-N 4-[(3-fluorophenyl)methyl]piperidine Chemical compound FC1=CC=CC(CC2CCNCC2)=C1 ZXAPMANOWGBURM-UHFFFAOYSA-N 0.000 description 2
- RIMFOUPCWRHPHG-UHFFFAOYSA-N 4-[(3-methylphenyl)methyl]piperidine Chemical compound CC1=CC=CC(CC2CCNCC2)=C1 RIMFOUPCWRHPHG-UHFFFAOYSA-N 0.000 description 2
- IIOSSRAPJYRUET-UHFFFAOYSA-N 4-[(4-chlorophenyl)methyl]-n-(4-phenylmethoxybenzoyl)piperidine-1-carboxamide Chemical compound C1=CC(Cl)=CC=C1CC1CCN(C(=O)NC(=O)C=2C=CC(OCC=3C=CC=CC=3)=CC=2)CC1 IIOSSRAPJYRUET-UHFFFAOYSA-N 0.000 description 2
- QALNMZDXQOHHHJ-UHFFFAOYSA-N 4-[(4-methoxyphenyl)methyl]-n-(4-phenylmethoxybenzoyl)piperidine-1-carboxamide Chemical compound C1=CC(OC)=CC=C1CC1CCN(C(=O)NC(=O)C=2C=CC(OCC=3C=CC=CC=3)=CC=2)CC1 QALNMZDXQOHHHJ-UHFFFAOYSA-N 0.000 description 2
- MHCNBVDZKQLGMD-UHFFFAOYSA-N 4-[(4-methylphenyl)methyl]-n-(4-phenylmethoxybenzoyl)piperidine-1-carboxamide Chemical compound C1=CC(C)=CC=C1CC1CCN(C(=O)NC(=O)C=2C=CC(OCC=3C=CC=CC=3)=CC=2)CC1 MHCNBVDZKQLGMD-UHFFFAOYSA-N 0.000 description 2
- FGXTXVCNSQMQBZ-UHFFFAOYSA-N 4-[(4-tert-butylphenyl)methyl]-n-(4-hydroxybenzoyl)piperidine-1-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1CC1CCN(C(=O)NC(=O)C=2C=CC(O)=CC=2)CC1 FGXTXVCNSQMQBZ-UHFFFAOYSA-N 0.000 description 2
- HLUHIBIKWNUTKF-UHFFFAOYSA-N 4-[(4-tert-butylphenyl)methyl]-n-(4-phenylmethoxybenzoyl)piperidine-1-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1CC1CCN(C(=O)NC(=O)C=2C=CC(OCC=3C=CC=CC=3)=CC=2)CC1 HLUHIBIKWNUTKF-UHFFFAOYSA-N 0.000 description 2
- SNLQMQQLVWGSHE-UHFFFAOYSA-N 4-benzyl-n-(4-nitrobenzoyl)piperidine-1-carboxamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)NC(=O)N1CCC(CC=2C=CC=CC=2)CC1 SNLQMQQLVWGSHE-UHFFFAOYSA-N 0.000 description 2
- JBJYFHLMYCGYGK-UHFFFAOYSA-N 4-benzyl-n-(4-phenylmethoxybenzoyl)piperidine-1-carboxamide Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(=O)NC(=O)C(C=C1)=CC=C1OCC1=CC=CC=C1 JBJYFHLMYCGYGK-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- XISPDFMAOWZEQG-UHFFFAOYSA-N 4h-1,4-oxazin-3-one Chemical group O=C1COC=CN1 XISPDFMAOWZEQG-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 2
- 102000038100 NR2 subfamily Human genes 0.000 description 2
- 108020002076 NR2 subfamily Proteins 0.000 description 2
- SAYXATYKEWOHLQ-UHFFFAOYSA-N OC1=CC=C(C(=O)NC(=O)N2CCC(CC2)CC2=CC(=CC=C2)C)C=C1 Chemical compound OC1=CC=C(C(=O)NC(=O)N2CCC(CC2)CC2=CC(=CC=C2)C)C=C1 SAYXATYKEWOHLQ-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 239000003875 Wang resin Substances 0.000 description 2
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 230000000181 anti-adherent effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- RMWYXTUXQXGDBW-UHFFFAOYSA-N methyl 4-(piperidin-4-ylmethyl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CC1CCNCC1 RMWYXTUXQXGDBW-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- IKLAWTBCMDRBRH-UHFFFAOYSA-N n-(4-benzylpiperidine-1-carbonyl)-2-oxo-3h-1,3-benzoxazole-6-carboxamide Chemical compound C=1C=C2NC(=O)OC2=CC=1C(=O)NC(=O)N(CC1)CCC1CC1=CC=CC=C1 IKLAWTBCMDRBRH-UHFFFAOYSA-N 0.000 description 2
- LNPRHUONRCDQFQ-UHFFFAOYSA-N n-(4-hydroxybenzoyl)-4-phenoxypiperidine-1-carboxamide Chemical compound C1=CC(O)=CC=C1C(=O)NC(=O)N1CCC(OC=2C=CC=CC=2)CC1 LNPRHUONRCDQFQ-UHFFFAOYSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- FLIHFLFEJNHHDE-UHFFFAOYSA-N tert-butyl 4-(4-chlorophenoxy)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC=C(Cl)C=C1 FLIHFLFEJNHHDE-UHFFFAOYSA-N 0.000 description 2
- DSKZTOYYGLSSDU-UHFFFAOYSA-N tert-butyl 4-[(2,4-difluorophenyl)methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CC1=CC=C(F)C=C1F DSKZTOYYGLSSDU-UHFFFAOYSA-N 0.000 description 2
- GYXIKJMCZIKFFI-UHFFFAOYSA-N tert-butyl 4-[(2,4-difluorophenyl)methylidene]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1=CC1=CC=C(F)C=C1F GYXIKJMCZIKFFI-UHFFFAOYSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- XVJSVNGWNDZUGK-UHFFFAOYSA-N (3-cyanophenyl)methyl dihydrogen phosphate Chemical compound OP(O)(=O)OCC1=CC=CC(C#N)=C1 XVJSVNGWNDZUGK-UHFFFAOYSA-N 0.000 description 1
- YHHXSPQXJBHAEO-UHFFFAOYSA-N (3-fluorophenyl)methyl dihydrogen phosphate Chemical compound OP(O)(=O)OCC1=CC=CC(F)=C1 YHHXSPQXJBHAEO-UHFFFAOYSA-N 0.000 description 1
- PJRFXRQVGLEOGZ-UHFFFAOYSA-N (3-methylphenyl)methyl dihydrogen phosphate Chemical compound CC1=CC=CC(COP(O)(O)=O)=C1 PJRFXRQVGLEOGZ-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- BCRQVSRWRCLQRV-UHFFFAOYSA-N 1,2-dichloroethane;hydrate Chemical compound O.ClCCCl BCRQVSRWRCLQRV-UHFFFAOYSA-N 0.000 description 1
- RBIZQDIIVYJNRS-UHFFFAOYSA-N 1,3-benzothiazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2SC=NC2=C1 RBIZQDIIVYJNRS-UHFFFAOYSA-N 0.000 description 1
- UMURLIQHQSKULR-UHFFFAOYSA-N 1,3-oxazolidine-2-thione Chemical compound S=C1NCCO1 UMURLIQHQSKULR-UHFFFAOYSA-N 0.000 description 1
- QUGUFLJIAFISSW-UHFFFAOYSA-N 1,4-difluorobenzene Chemical compound FC1=CC=C(F)C=C1 QUGUFLJIAFISSW-UHFFFAOYSA-N 0.000 description 1
- DCEXCMVFRCTUOL-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]piperidine Chemical compound C1=CC(Cl)=CC=C1CN1CCCCC1 DCEXCMVFRCTUOL-UHFFFAOYSA-N 0.000 description 1
- JNFARRUAVZLJII-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperidine;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1CN1CCCCC1 JNFARRUAVZLJII-UHFFFAOYSA-N 0.000 description 1
- DGSQXYGFDGFQLQ-UHFFFAOYSA-N 1-[(4-methoxyphenyl)methyl]piperidine Chemical compound C1=CC(OC)=CC=C1CN1CCCCC1 DGSQXYGFDGFQLQ-UHFFFAOYSA-N 0.000 description 1
- JSGULDBTVVNANL-UHFFFAOYSA-N 1-[(4-methylphenyl)methyl]piperidine Chemical compound C1=CC(C)=CC=C1CN1CCCCC1 JSGULDBTVVNANL-UHFFFAOYSA-N 0.000 description 1
- RJCGZNCCVKIBHO-UHFFFAOYSA-N 1-chloro-4-fluorobenzene Chemical compound FC1=CC=C(Cl)C=C1 RJCGZNCCVKIBHO-UHFFFAOYSA-N 0.000 description 1
- SQSJADMOVKSAQY-UHFFFAOYSA-N 1-ethoxy-2-fluorobenzene Chemical compound CCOC1=CC=CC=C1F SQSJADMOVKSAQY-UHFFFAOYSA-N 0.000 description 1
- NUNZGJKXTJMXGY-UHFFFAOYSA-N 1H-indole-2-carboximidamide Chemical class C1=CC=C2NC(C(=N)N)=CC2=C1 NUNZGJKXTJMXGY-UHFFFAOYSA-N 0.000 description 1
- GQMYQEAXTITUAE-UHFFFAOYSA-N 1H-indole-5-carboxamide Chemical compound NC(=O)C1=CC=C2NC=CC2=C1 GQMYQEAXTITUAE-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OQUFOZNPBIIJTN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OQUFOZNPBIIJTN-UHFFFAOYSA-N 0.000 description 1
- BZRKWTCIDCRBMY-UHFFFAOYSA-N 2-oxo-3h-1,3-benzoxazole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2NC(=O)OC2=C1 BZRKWTCIDCRBMY-UHFFFAOYSA-N 0.000 description 1
- FNLQDVXHDNFXIY-UHFFFAOYSA-N 3h-benzimidazole-5-carboxamide Chemical compound NC(=O)C1=CC=C2NC=NC2=C1 FNLQDVXHDNFXIY-UHFFFAOYSA-N 0.000 description 1
- LELTYNIPRLOYCM-UHFFFAOYSA-N 4-(4-chlorophenoxy)piperidin-1-ium;chloride Chemical compound Cl.C1=CC(Cl)=CC=C1OC1CCNCC1 LELTYNIPRLOYCM-UHFFFAOYSA-N 0.000 description 1
- FFFNUHGMXGAUFY-UHFFFAOYSA-N 4-(4-methylphenoxy)piperidine Chemical compound C1=CC(C)=CC=C1OC1CCNCC1 FFFNUHGMXGAUFY-UHFFFAOYSA-N 0.000 description 1
- BREBKAKBNYXIOP-UHFFFAOYSA-N 4-(phenoxymethyl)piperidine Chemical compound C1CNCCC1COC1=CC=CC=C1 BREBKAKBNYXIOP-UHFFFAOYSA-N 0.000 description 1
- XZGLJQNFFQYLES-UHFFFAOYSA-N 4-(phenylsulfanylmethyl)piperidine;hydrochloride Chemical compound Cl.C1CNCCC1CSC1=CC=CC=C1 XZGLJQNFFQYLES-UHFFFAOYSA-N 0.000 description 1
- CKNQEVWLVDSORN-UHFFFAOYSA-N 4-[(3,4-difluorophenyl)methyl]-n-(4-hydroxybenzoyl)piperidine-1-carboxamide Chemical compound C1=CC(O)=CC=C1C(=O)NC(=O)N1CCC(CC=2C=C(F)C(F)=CC=2)CC1 CKNQEVWLVDSORN-UHFFFAOYSA-N 0.000 description 1
- GTIPRWLJTBFXAB-UHFFFAOYSA-N 4-[(3,4-difluorophenyl)methyl]piperidine Chemical compound C1=C(F)C(F)=CC=C1CC1CCNCC1 GTIPRWLJTBFXAB-UHFFFAOYSA-N 0.000 description 1
- ALRQMSIQBWRMRX-UHFFFAOYSA-N 4-[(4-fluorophenyl)methyl]-n-[4-(methanesulfonamido)benzoyl]piperidine-1-carboxamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1C(=O)NC(=O)N1CCC(CC=2C=CC(F)=CC=2)CC1 ALRQMSIQBWRMRX-UHFFFAOYSA-N 0.000 description 1
- OJKWWANXBGLGQN-UHFFFAOYSA-N 4-[(4-fluorophenyl)methyl]piperidine;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1CC1CCNCC1 OJKWWANXBGLGQN-UHFFFAOYSA-N 0.000 description 1
- WOOPTEWYQWYUGW-UHFFFAOYSA-N 4-[(4-methylphenyl)methyl]piperidine Chemical compound C1=CC(C)=CC=C1CC1CCNCC1 WOOPTEWYQWYUGW-UHFFFAOYSA-N 0.000 description 1
- XQDVRUGUNUMSOJ-UHFFFAOYSA-N 4-[(4-tert-butylphenyl)methyl]piperidine Chemical compound C1=CC(C(C)(C)C)=CC=C1CC1CCNCC1 XQDVRUGUNUMSOJ-UHFFFAOYSA-N 0.000 description 1
- CBHRLPOIZTWXCI-UHFFFAOYSA-N 4-[2-(4-methoxyphenyl)ethyl]piperidine Chemical compound C1=CC(OC)=CC=C1CCC1CCNCC1 CBHRLPOIZTWXCI-UHFFFAOYSA-N 0.000 description 1
- UAMOWMWECFNJHB-UHFFFAOYSA-N 4-[2-(4-methylphenyl)ethyl]piperidine Chemical compound C1=CC(C)=CC=C1CCC1CCNCC1 UAMOWMWECFNJHB-UHFFFAOYSA-N 0.000 description 1
- DOUKFDZHIACTLD-UHFFFAOYSA-N 4-[[4-(trifluoromethyl)phenyl]methyl]piperidine Chemical compound C1=CC(C(F)(F)F)=CC=C1CC1CCNCC1 DOUKFDZHIACTLD-UHFFFAOYSA-N 0.000 description 1
- PZRNYSSNDQNQNR-UHFFFAOYSA-N 4-[fluoro(phenyl)methyl]-N-(4-phenylmethoxybenzoyl)piperidine-1-carboxamide Chemical compound C=1C=CC=CC=1C(F)C(CC1)CCN1C(=O)NC(=O)C(C=C1)=CC=C1OCC1=CC=CC=C1 PZRNYSSNDQNQNR-UHFFFAOYSA-N 0.000 description 1
- VJRVWKNLYQJGCU-UHFFFAOYSA-N 4-benzylpiperidine-1-carboxylic acid 4-(methanesulfonamido)benzamide Chemical compound CS(=O)(=O)NC1=CC=C(C(N)=O)C=C1.C1CN(C(=O)O)CCC1CC1=CC=CC=C1 VJRVWKNLYQJGCU-UHFFFAOYSA-N 0.000 description 1
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
- BBMFSGOFUHEVNP-UHFFFAOYSA-N 4-hydroxy-2-methylbenzoic acid Chemical compound CC1=CC(O)=CC=C1C(O)=O BBMFSGOFUHEVNP-UHFFFAOYSA-N 0.000 description 1
- ZESWUEBPRPGMTP-UHFFFAOYSA-N 4-nitrobenzamide Chemical compound NC(=O)C1=CC=C([N+]([O-])=O)C=C1 ZESWUEBPRPGMTP-UHFFFAOYSA-N 0.000 description 1
- KBYPITRKIJKGMD-UHFFFAOYSA-N 4-phenoxypiperidine Chemical compound C1CNCCC1OC1=CC=CC=C1 KBYPITRKIJKGMD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- RJQHGFXSBXKETK-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=CC=C(C(=O)NC(=O)N2CCC(CC2)CC2=CC=C(C=C2)F)C=C1 Chemical compound C(C1=CC=CC=C1)OC1=CC=C(C(=O)NC(=O)N2CCC(CC2)CC2=CC=C(C=C2)F)C=C1 RJQHGFXSBXKETK-UHFFFAOYSA-N 0.000 description 1
- COFIJAAPDYWPQV-UHFFFAOYSA-N C1(=CC=C(C=C1)S(=O)(=O)NC1=CC=C(C(=O)NC(=O)N2CCC(CC2)CC2=CC=CC=C2)C=C1)C Chemical compound C1(=CC=C(C=C1)S(=O)(=O)NC1=CC=C(C(=O)NC(=O)N2CCC(CC2)CC2=CC=CC=C2)C=C1)C COFIJAAPDYWPQV-UHFFFAOYSA-N 0.000 description 1
- MSLDHGSCXBCRQD-UHFFFAOYSA-N C1CN(C(=O)O)CCC1CC1=CC=CC=C1.C1=CC(C(=O)N)=CC=C1NC(=O)C1=CC=C(Cl)C=C1 Chemical compound C1CN(C(=O)O)CCC1CC1=CC=CC=C1.C1=CC(C(=O)N)=CC=C1NC(=O)C1=CC=C(Cl)C=C1 MSLDHGSCXBCRQD-UHFFFAOYSA-N 0.000 description 1
- 108091005462 Cation channels Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102100038942 Glutamate receptor ionotropic, NMDA 3A Human genes 0.000 description 1
- 102100038958 Glutamate receptor ionotropic, NMDA 3B Human genes 0.000 description 1
- 101710195174 Glutamate receptor ionotropic, NMDA 3B Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- CNRCFIGHPLJSLI-UHFFFAOYSA-N N-(4-benzylpiperidine-1-carbonyl)-2H-benzotriazole-5-carboxamide Chemical compound N1N=NC2=C1C=CC(=C2)C(=O)NC(=O)N2CCC(CC2)CC2=CC=CC=C2 CNRCFIGHPLJSLI-UHFFFAOYSA-N 0.000 description 1
- WUOBVHUVKTVMOJ-UHFFFAOYSA-N N-(4-benzylpiperidine-1-carbonyl)-3H-benzimidazole-5-carboxamide Chemical compound N1C=NC2=C1C=CC(=C2)C(=O)NC(=O)N2CCC(CC2)CC2=CC=CC=C2 WUOBVHUVKTVMOJ-UHFFFAOYSA-N 0.000 description 1
- LMQDLMGZQSNTSO-UHFFFAOYSA-N N-(4-hydroxybenzoyl)-4-(4-methylphenoxy)piperidine-1-carboxamide Chemical compound C1=CC(C)=CC=C1OC1CCN(C(=O)NC(=O)C=2C=CC(O)=CC=2)CC1 LMQDLMGZQSNTSO-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 108010017769 NR2A NMDA receptor Proteins 0.000 description 1
- 108010054200 NR2B NMDA receptor Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- CZTXCLJEUHQQLM-UHFFFAOYSA-N OP(O)(=O)OCC1=CC=C(F)C=C1F Chemical compound OP(O)(=O)OCC1=CC=C(F)C=C1F CZTXCLJEUHQQLM-UHFFFAOYSA-N 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000012435 analytical chromatography Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000002864 food coloring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000001034 iron oxide pigment Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- JZINAHURFYPYST-UHFFFAOYSA-N methyl 4-(phosphonooxymethyl)benzoate Chemical compound COC(=O)C1=CC=C(COP(O)(O)=O)C=C1 JZINAHURFYPYST-UHFFFAOYSA-N 0.000 description 1
- WZLGLQHTDBQFHF-UHFFFAOYSA-N methyl 4-[[1-[(4-hydroxybenzoyl)carbamoyl]piperidin-4-yl]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CC1CCN(C(=O)NC(=O)C=2C=CC(O)=CC=2)CC1 WZLGLQHTDBQFHF-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- PDAQKGMZRCVCFJ-UHFFFAOYSA-N n-(4-acetamidobenzoyl)-4-(4-chlorophenoxy)piperidine-1-carboxamide Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC(=O)N1CCC(OC=2C=CC(Cl)=CC=2)CC1 PDAQKGMZRCVCFJ-UHFFFAOYSA-N 0.000 description 1
- GYMCNADUHSVZDC-UHFFFAOYSA-N n-(4-acetamidobenzoyl)-4-[(4-fluorophenyl)methyl]piperidine-1-carboxamide Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC(=O)N1CCC(CC=2C=CC(F)=CC=2)CC1 GYMCNADUHSVZDC-UHFFFAOYSA-N 0.000 description 1
- KYIDXLQENQASRK-UHFFFAOYSA-N n-(4-benzylpiperidine-1-carbonyl)-1h-indole-5-carboxamide Chemical compound C=1C=C2NC=CC2=CC=1C(=O)NC(=O)N(CC1)CCC1CC1=CC=CC=C1 KYIDXLQENQASRK-UHFFFAOYSA-N 0.000 description 1
- FQRFAWPOJUWSKH-UHFFFAOYSA-N n-(4-hydroxybenzoyl)-4-(phenoxymethyl)piperidine-1-carboxamide Chemical compound C1=CC(O)=CC=C1C(=O)NC(=O)N1CCC(COC=2C=CC=CC=2)CC1 FQRFAWPOJUWSKH-UHFFFAOYSA-N 0.000 description 1
- XVOJZQXQGNOAQH-UHFFFAOYSA-N n-(4-hydroxybenzoyl)-4-[2-(4-methoxyphenyl)ethyl]piperidine-1-carboxamide Chemical compound C1=CC(OC)=CC=C1CCC1CCN(C(=O)NC(=O)C=2C=CC(O)=CC=2)CC1 XVOJZQXQGNOAQH-UHFFFAOYSA-N 0.000 description 1
- OWYBROBJWOMMRK-UHFFFAOYSA-N n-(4-hydroxybenzoyl)-4-[2-(4-methylphenyl)ethyl]piperidine-1-carboxamide Chemical compound C1=CC(C)=CC=C1CCC1CCN(C(=O)NC(=O)C=2C=CC(O)=CC=2)CC1 OWYBROBJWOMMRK-UHFFFAOYSA-N 0.000 description 1
- NFCKOGJVSQNAKZ-UHFFFAOYSA-N n-(4-hydroxybenzoyl)-4-[[4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxamide Chemical compound C1=CC(O)=CC=C1C(=O)NC(=O)N1CCC(CC=2C=CC(=CC=2)C(F)(F)F)CC1 NFCKOGJVSQNAKZ-UHFFFAOYSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 108091008589 nuclear estrogen receptors Proteins 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- XYKIUTSFQGXHOW-UHFFFAOYSA-N propan-2-one;toluene Chemical compound CC(C)=O.CC1=CC=CC=C1 XYKIUTSFQGXHOW-UHFFFAOYSA-N 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002385 psychotomimetic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 210000001055 substantia gelatinosa Anatomy 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- RXNQBVRCZIYUJK-UHFFFAOYSA-N tert-butyl 4-(methylsulfonyloxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(COS(C)(=O)=O)CC1 RXNQBVRCZIYUJK-UHFFFAOYSA-N 0.000 description 1
- FWCHBCLJFAXWOI-UHFFFAOYSA-N tert-butyl 4-(phenylsulfanylmethyl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CSC1=CC=CC=C1 FWCHBCLJFAXWOI-UHFFFAOYSA-N 0.000 description 1
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0401524A HU227000B1 (en) | 2004-07-29 | 2004-07-29 | Nmda receptor antagonist benzoyl urea derivatives, and pharmaceutical compositions containing them |
AP2006003841A AP2006003841A0 (en) | 2004-07-29 | 2005-07-21 | New benzoyl urea derivatives |
GEAP20059894A GEP20094607B (en) | 2004-07-29 | 2005-07-21 | New benzoyl urea derivatives |
EP05764413A EP1771429A1 (de) | 2004-07-29 | 2005-07-21 | Neue benzoylharnstoffderivate |
US11/658,788 US20090170901A1 (en) | 2004-07-29 | 2005-07-21 | Benzoyl Urea Derivatives |
CNA2005800241971A CN1989119A (zh) | 2004-07-29 | 2005-07-21 | 新的苯甲酰脲衍生物 |
BRPI0513924-4A BRPI0513924A (pt) | 2004-07-29 | 2005-07-21 | novos derivados de benzoil uréia |
AU2005266161A AU2005266161A1 (en) | 2004-07-29 | 2005-07-21 | New benzoyl urea derivatives |
EA200700366A EA010893B1 (ru) | 2004-07-29 | 2005-07-21 | Новые производные бензоилмочевины |
CA002574158A CA2574158A1 (en) | 2004-07-29 | 2005-07-21 | New benzoyl urea derivatives |
MX2007001042A MX2007001042A (es) | 2004-07-29 | 2005-07-21 | Nuevos derivados de benzoilurea. |
JP2007523162A JP2008508249A (ja) | 2004-07-29 | 2005-07-21 | 新規なベンゾイル尿素誘導体 |
PCT/HU2005/000079 WO2006010966A1 (en) | 2004-07-29 | 2005-07-21 | New benzoyl urea derivatives |
KR1020077000264A KR20070039033A (ko) | 2004-07-29 | 2005-07-21 | 신규 벤조일 우레아 유도체 |
IL179486A IL179486A0 (en) | 2004-07-29 | 2006-11-22 | New benzoyl urea derivatives |
ZA200700322A ZA200700322B (en) | 2004-07-29 | 2007-01-11 | New benzoyl urea derivatives |
TNP2007000017A TNSN07017A1 (en) | 2004-07-29 | 2007-01-17 | New benzoyl urea derivatives |
MA29704A MA28817B1 (fr) | 2004-07-29 | 2007-02-22 | Nouveaux derives d'uree benzoyle |
NO20071110A NO20071110L (no) | 2004-07-29 | 2007-02-27 | Nye benzoylureaderivater |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0401524A HU227000B1 (en) | 2004-07-29 | 2004-07-29 | Nmda receptor antagonist benzoyl urea derivatives, and pharmaceutical compositions containing them |
Publications (3)
Publication Number | Publication Date |
---|---|
HU0401524D0 HU0401524D0 (en) | 2004-09-28 |
HUP0401524A2 HUP0401524A2 (en) | 2006-05-29 |
HU227000B1 true HU227000B1 (en) | 2010-04-28 |
Family
ID=89985409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0401524A HU227000B1 (en) | 2004-07-29 | 2004-07-29 | Nmda receptor antagonist benzoyl urea derivatives, and pharmaceutical compositions containing them |
Country Status (19)
Country | Link |
---|---|
US (1) | US20090170901A1 (de) |
EP (1) | EP1771429A1 (de) |
JP (1) | JP2008508249A (de) |
KR (1) | KR20070039033A (de) |
CN (1) | CN1989119A (de) |
AP (1) | AP2006003841A0 (de) |
AU (1) | AU2005266161A1 (de) |
BR (1) | BRPI0513924A (de) |
CA (1) | CA2574158A1 (de) |
EA (1) | EA010893B1 (de) |
GE (1) | GEP20094607B (de) |
HU (1) | HU227000B1 (de) |
IL (1) | IL179486A0 (de) |
MA (1) | MA28817B1 (de) |
MX (1) | MX2007001042A (de) |
NO (1) | NO20071110L (de) |
TN (1) | TNSN07017A1 (de) |
WO (1) | WO2006010966A1 (de) |
ZA (1) | ZA200700322B (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8114843B2 (en) | 2005-11-18 | 2012-02-14 | The Regents Of The University Of California | Photoreactive regulator of protein function and methods of use thereof |
US7935706B2 (en) | 2006-02-23 | 2011-05-03 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
CA2665804A1 (en) * | 2006-08-23 | 2008-02-28 | Astellas Pharma Inc. | Urea compound or salt thereof |
AU2011216950A1 (en) | 2010-02-16 | 2012-08-23 | Pfizer Inc. | (R)-4-((4-((4-(tetrahydrofuran-3-yloxy) benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol, a partial agonist of 5-HT4 receptors |
CN102532062B (zh) * | 2010-12-08 | 2013-12-04 | 上海工程技术大学 | 一种苯甲酰脲化合物及其合成方法 |
KR101481952B1 (ko) | 2012-04-13 | 2015-01-22 | 한국과학기술연구원 | 신경보호제로서의 유레아 유도체 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2882273A (en) * | 1958-02-07 | 1959-04-14 | Bristol Lab Inc | Therapeutic agents |
US4152430A (en) * | 1977-09-22 | 1979-05-01 | William H. Rorer, Inc. | Synergistic compositions and method of use |
EP1186303A3 (de) * | 2000-09-06 | 2003-12-10 | Pfizer Products Inc. | Ein Neutrophilhemmender Faktor und ein selektive NMDA-NR2B Rezeptor Antagonisten enthaltende Kombinationspräparate zur Behandlung von Schlaganfällen und traumatischen Gehirnschäden |
DK1409477T3 (da) * | 2001-07-24 | 2008-12-08 | Richter Gedeon Nyrt | Piperdinderivater som NMDA receptorantagonister |
-
2004
- 2004-07-29 HU HU0401524A patent/HU227000B1/hu unknown
-
2005
- 2005-07-21 GE GEAP20059894A patent/GEP20094607B/en unknown
- 2005-07-21 BR BRPI0513924-4A patent/BRPI0513924A/pt not_active IP Right Cessation
- 2005-07-21 KR KR1020077000264A patent/KR20070039033A/ko not_active Application Discontinuation
- 2005-07-21 CN CNA2005800241971A patent/CN1989119A/zh active Pending
- 2005-07-21 AU AU2005266161A patent/AU2005266161A1/en not_active Abandoned
- 2005-07-21 AP AP2006003841A patent/AP2006003841A0/xx unknown
- 2005-07-21 JP JP2007523162A patent/JP2008508249A/ja not_active Withdrawn
- 2005-07-21 CA CA002574158A patent/CA2574158A1/en not_active Abandoned
- 2005-07-21 WO PCT/HU2005/000079 patent/WO2006010966A1/en active Application Filing
- 2005-07-21 MX MX2007001042A patent/MX2007001042A/es not_active Application Discontinuation
- 2005-07-21 US US11/658,788 patent/US20090170901A1/en not_active Abandoned
- 2005-07-21 EP EP05764413A patent/EP1771429A1/de not_active Withdrawn
- 2005-07-21 EA EA200700366A patent/EA010893B1/ru not_active IP Right Cessation
-
2006
- 2006-11-22 IL IL179486A patent/IL179486A0/en unknown
-
2007
- 2007-01-11 ZA ZA200700322A patent/ZA200700322B/en unknown
- 2007-01-17 TN TNP2007000017A patent/TNSN07017A1/en unknown
- 2007-02-22 MA MA29704A patent/MA28817B1/fr unknown
- 2007-02-27 NO NO20071110A patent/NO20071110L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX2007001042A (es) | 2007-04-16 |
KR20070039033A (ko) | 2007-04-11 |
EA010893B1 (ru) | 2008-12-30 |
CA2574158A1 (en) | 2006-02-02 |
HU0401524D0 (en) | 2004-09-28 |
AU2005266161A1 (en) | 2006-02-02 |
TNSN07017A1 (en) | 2008-06-02 |
ZA200700322B (en) | 2008-05-28 |
GEP20094607B (en) | 2009-02-10 |
WO2006010966A1 (en) | 2006-02-02 |
IL179486A0 (en) | 2007-05-15 |
NO20071110L (no) | 2007-02-27 |
CN1989119A (zh) | 2007-06-27 |
US20090170901A1 (en) | 2009-07-02 |
BRPI0513924A (pt) | 2008-05-20 |
EP1771429A1 (de) | 2007-04-11 |
JP2008508249A (ja) | 2008-03-21 |
EA200700366A1 (ru) | 2007-08-31 |
MA28817B1 (fr) | 2007-08-01 |
AP2006003841A0 (en) | 2006-12-31 |
HUP0401524A2 (en) | 2006-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7375116B2 (en) | Amide derivatives as NMDA receptor antagonists | |
US6130235A (en) | Compounds and methods to treat cardiac failure and other disorders | |
US20030073699A1 (en) | Compounds and methods to treat cardiac failure and other disorders | |
EP1773810B1 (de) | Neue 4-benzylidenpiperidinderivate | |
TWI450893B (zh) | Inhibition of prostaglandin D synthase in the piper Compounds | |
IL159393A (en) | Piperidine derivatives, pharmaceutical compositions containing them, processes for their preparation and uses thereof | |
KR20010070946A (ko) | 심장병 및 다른 질병을 치료하기 위한 헤테로 고리 화합물및 그 치료 방법 | |
US20080300276A1 (en) | Heterocyclic Carboxylic Acide Amide Derivatives | |
US20090012118A1 (en) | Kynurenic Acid Amide Derivatives as Nr2b Receptor Antagoni | |
JP2008508249A (ja) | 新規なベンゾイル尿素誘導体 | |
HU226978B1 (en) | New carboxylic acid amide compounds, process for their preparation and pharmaceutical compositions containing them and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC9A | Change of name, address |
Owner name: RICHTER GEDEON NYRT., HU Free format text: FORMER OWNER(S): RICHTER GEDEON VEGYESZETI GYAR RT., HU |